May 23, 2017
Recommended Topic Related To:

Hycamtin Capsules

"The US Food and Drug Administration (FDA) has approved the immunotherapy drug atezolizumab (Tecentriq, Genentech) for use in patients with metastatic non-small cell lung cancer (NSCLC) who have progressed during or after treatment with a"...


Hycamtin Capsules



Overdoses (up to 5-fold of the prescribed dose) occurred in patients treated with HYCAMTIN capsules. The primary complication of overdosage is bone marrow suppression. The observed signs and symptoms of overdose are consistent with the known adverse reactions associated with HYCAMTIN for oral use [see ADVERSE REACTIONS]. Mucositis has also been reported in association with overdose.

There is no known antidote for overdosage with HYCAMTIN. If an overdose is suspected, monitor the patient closely for bone marrow suppression, and institute supportive-care measures (such as the prophylactic use of G-CSF and/or antibiotic therapy) as appropriate.


HYCAMTIN is contraindicated in patients who have a history of severe hypersensitivity reactions to topotecan.

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 12/8/2016


Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Get the latest treatment options.

Related Drugs
Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations